Article

Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway

2021-11-04

Abstract excerpt

<h4>Background: </h4> Gemcitabine (GEM) is a chemotherapeutic drug used to treat pancreatic ductal adenocarcinoma carcinoma (PDAC), but chemoresistance is often encountered clinically. Nrf2, an oxidative stress responsive transcription factor, is an important contributor to chemoresistance and is closely associated with poor prognosis of PDAC. Brucein D (BD), a natural compound has been reported to exert anti-tumo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8539b76c-41fa-59f6-b446-f1985e0f6f3a
DOI: 10.21203/rs.3.rs-1025895/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathwayDOI 10.21203/rs.3.rs-1025895/v1Read

USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2Semantic proximity Read

Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis.Semantic proximity Read

The ‘N-factors’ in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancerSemantic proximity Read

Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabineSemantic proximity Read

Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancerSemantic proximity Read

Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.Semantic proximity Read

Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer.Semantic proximity Read

PGM3 inhibition shows cooperative effects with erastin inducing pancreatic cancer cell death via activation of the unfolded protein responseSemantic proximity Read

ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancerSemantic proximity Read

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.Semantic proximity Read

The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells upon Stimulation of Reactive Oxygen SpeciesSemantic proximity Read

Combination of RUNX1 inhibitor and gemcitabine to mitigate chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2a-axis-mediated endoplasmic reticulum stressSemantic proximity Read